“First-Line Treatment of Patients With HER2-Positive Metastatic Gastric and Gastroesophageal Junction Cancer”. 2022. Biomolecules and Biomedicine 22 (5): 818-25. https://doi.org/10.17305/bjbms.2021.7069.